Portal de recerca
Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Almirante, B
- Garnacho-Montero, J
- Maseda, E
- Candel, FJ
- Grau, S
- Guinea, J
- Muñoz P
- Ruiz-Santana, S
Grups d'Investigació
Abstract
Introduction. Invasive infections caused by Candida spp. in critically ill patients may significantly worsen their prognosis, so it is of great importance to establish an early detection and a suitable therapeutic strategy. The objective of this study was to define the differential role of echinocandins in treating certain critical patient profiles. Methodology. A scientific committee of 9 experts in infectious diseases, critical care, microbiology, and hospital pharmacy reviewed the existing evidence on the treatment of candidemia and invasive candidiasis in critically ill patients. After that, a questionnaire with 35 items was elaborated to be agreed by 26 specialists in the aforementioned disciplines using a modified Delphi method. Results. After two rounds of evaluation, a consensus was reached in terms of agreement in 66% of the items. Some of the consensuses achieved included: it is not necessary to adjust the dose of echinocandins during renal replacement therapy; the echinocandins are the empirical and/or directed treatment of choice for candidemia and invasive candidiasis associated with biofilms; these drugs may be used in the antifungal prophylaxis of high-risk liver transplantation. In the absence of additional clinical data, it should be noted that micafungin is the echinocandin with the most available scientific evidence. Conclusions. The experts consulted showed a high degree of agreement on some of the most controversial aspects regarding the management of candidemia and invasive candidiasis in critical patients, which could inform of practical recommendations for their treatment.
Dades de la publicació
- ISSN/ISSNe:
- 0214-3429, 1988-9518
- Tipus:
- Article
- Pàgines:
- 355-367
- PubMed:
- 28945064
- Factor d'Impacte:
- 0,254 SCImago ℠
- Quartil:
- Q3 SCImago ℠
REVISTA ESPANOLA DE QUIMIOTERAPIA SOCIEDAD ESPANOLA QUIMIOTERAPIA
Cites Rebudes en Web of Science: 3
Documents
- No hi ha documents
Mètriques
Filiacions
Keywords
- Critical patients; Candidemia; Invasive candidiasis; Antifungal therapy; Echinocandins
Projectes associats
ESTUDIO OBSERVACIONAL, PROSPECTIVO Y MULTICÉNTRICO, PARA DETERMINAR LA INCIDENCIA DE DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILE, FACTORES DE RIESGO Y PRONÓSTICO EN PACIENTES CRÍTICOS EN ESPAÑA.
Investigador Principal: MIGUEL ANGEL CHIVELI MONLEON
AST-ICD-2013-01 . 2014
DETERMINACIÓN DE LOS NIVELES PLASMÁTICOS DE MICAFUNGINA EN PACIENTES CRÍTICOS DURANTE EL TRATAMIENTO CON MEMBRANA DE OXIGENACIÓN EXTRACORPOREA.
Investigador Principal: IGNACIO MORENO PUIGDOLLERS
LOP-MIC-2014-01 . 2015
TRATAMIENTO ANTICIPADO CON GANCICLOVIR DE LA INFECCIÓN ACTIVA POR EL CITOMEGALOVIRUS (CMV) EN EL PACIENTE CRÍTICO EN VENTILACIÓN MECÁNICA CON SEPSIS GRAVE O SHOCK SÉPTICO.
Investigador Principal: MIGUEL ANGEL CHIVELI MONLEON
GANCMV-2011